Amgen (AMGN) Offering Possible 26.26% Return Over the Next 15 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $175.00 short put and a strike $170.00 long put offers a potential 26.26% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $175.00 by expiration. The full premium credit of $1.04 would be kept by the premium seller. The risk of $3.96 would be incurred if the stock dropped below the $170.00 long put strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.

The RSI indicator is at 26.14 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

Edited Transcript of AMGN earnings conference call or presentation 30-Apr-19 9:00pm GMT
Wed, 01 May 2019 05:29:14 +0000
Q1 2019 Amgen Inc Earnings Call

Amgen Inc (AMGN) Q1 2019 Earnings Call Transcript
Wed, 01 May 2019 03:42:46 +0000
AMGN earnings call for the period ending March 31, 2019.

Amgen Reports an Unusual Slide Backward
Tue, 30 Apr 2019 23:37:00 +0000
The first three months of the year weren't nearly as positive as investors had hoped for.

Amgen revenue flat as migraine, cholesterol drugs miss sales expectations
Tue, 30 Apr 2019 23:25:42 +0000
Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure. Excluding items, Amgen earned $3.56 per share, topping analysts' average expectations by 9 cents, according to IBES data from Refinitiv. Share buybacks helped boost the EPS result, said Jefferies analyst Michael Yee.

Amgen Earnings: AMGN Stock Dips Slightly Despite Q1 EPS, Sales Beat
Tue, 30 Apr 2019 22:50:33 +0000
Amgen (NASDAQ:AMGN) reported its latest quarterly earnings figures late on Tuesday, bringing in earnings that were stronger than what analysts called for, yet it declined year-over-year, while sales of one of its key products were down, playing a role in AMGN stock retracing a touch.The Thousand Oaks, Calif.-based biopharmaceutical business said that for its first quarter of its fiscal 2019, it brought in net income of $2 billion, or $3.18 per share. The figure was 13% lower than it was during the same period in its fiscal 2018, when it brought in earnings of $2 billion, or $3.18 per share.On an adjusted basis when taking into account one-time items, Amgen said it brought in earnings of $3.56 per share, which is about 2.6% higher than the company's adjusted earnings from the same period in its fiscal 2018. Analysts were calling for the company to rake in adjusted earnings of $3.48 per share, according to a survey of analysts conducted by FactSet.InvestorPlace – Stock Market News, Stock Advice & Trading TipsThe company's revenue was flat when compared to its year-ago quarter, coming in at $5.6 billion, which did top the Wall Street guidance of $5.5 billion in sales, per FactSet. Amgen's weakest point during the period were sales of its drug Neulasta, which declined roughly 12% year-over-year, due in part to a lower net selling price, as well as inventory changes.The company's Enbrel drug sales gained 4%, due in part to "favorable impacts" from changes in account sales estimates.AMGN stock is down about 0.7% after the bell today due in part to the sales decline of its drug Neulasta, yet earnings were strong overall when compared to the year-ago quarter and what analysts projected. Shares had been down roughly 1% during regular trading hours ahead of the company's quarterly earnings report. More From InvestorPlace * 7 Stocks to Buy That Ought to Buy Back Shares * 7 Cloud Stocks to Buy Now * 7 A-Rated Stocks That Are Under $10 Compare Brokers The post Amgen Earnings: AMGN Stock Dips Slightly Despite Q1 EPS, Sales Beat appeared first on InvestorPlace.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.